Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors-Reference-Cited by-同舟云学术

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Published:2018-06-20 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Nayak-Kapoor Asha,Hao Zhonglin,Sadek Ramses,Dobbins Robin,Marshall Lisa,Vahanian Nicholas N.,Jay Ramsey W.,Kennedy Eugene,Mautino Mario R.,Link Charles J.,Lin Ray S.,Royer-Joo Stephanie,Liang Xiaorong,Salphati Laurent,Morrissey Kari M.,Mahrus Sami,McCall Bruce,Pirzkall Andrea,Munn David H.,Janik John E.,Khleif Samir N.

Funder

Genentech

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0351-9.pdf

Reference36 articles.

1. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37:193–207.

2. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3 dioxygenase. Nat Med. 2003;9:1269–74.

3. Desvignes L, Ernst JD. Interferon gamma responsive non hematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity. 2009;31:974–85.